Meet The New Teva: 8% Global Generics Share, 300 ANDAs, 1,500 Launches

 
• By Jessica Merrill
  
Generate a summary of this article
Listen to this article
Beta

The world’s generic drug leader has cemented its leadership position for the foreseeable future with the acquisition of Allergan’s generics business. Management outlined how it plans to grow the combined business by taking advantage of its size during an investor briefing.

pills

Teva Pharmaceutical Industries Ltd. has gained a substantial lead in the global generic drug market with the $40.5bn acquisition of Allergan PLC’s generic drug business, and now is counting on the size to help sustain its lead and drive growth. The combined company will have a global generic market share of 8% and will be in a position to launch 1,500 products around the world in 2017.

CEO Erez Vigodman, Global Generic Medicines CEO Sigurdur Olafsson and the rest of the newly established management team unveiled the...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Strategy

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.